Bendamustine: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France), NICE (England) and PHARMAC (New Zealand), among others, recommended or restricted bendamustine, while AWMSG (Wales) did not recommend it.
The file has been open for more than a decade: 13.5 years separate the first record, 5 Oct 2010 at AWMSG (Wales), from the most recent, 10 Apr 2024 at HAS (France).
PBAC (Australia) changed its position: not recommended in 2015, recommended by 2015, after a resubmission.
No assessment is on file from TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for bendamustine, 2 submissions were never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The programme is broad: 9 distinct indication wordings are recorded for bendamustine by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess bendamustine, on 5 Oct 2010; HAS (France) did not open a file until 6 Apr 2016 — a wide spread of 5.5 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 11 years in total.
6 of the 6 agencies here assessed bendamustine more than once, HAS (France) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for bendamustine.
The full ledger for bendamustine reads 15 recommended, 2 not recommended, 2 non-submission and 1 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 10 Apr 2024 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| PHARMAC (New Zealand) | 11 Feb 2016 | Non-Hodgkin lymphoma, indolent, first-line | PTAC advice: Low · decision reached | source |
| PBAC (Australia) | 2015 | Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma | The PBAC deferred its decision on bendamustine in previously untreated indolent Non-Hodgki… | source |
| SMC (Scotland) | 11 Apr 2011 | for the front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who ar… | not recommended | source |
| NICE (England) | 27 Oct 2010 | NICE TA206 | terminated appraisal | source |
18 further decisions for bendamustine, across 6 agencies, are not shown here. They link to 15 further source documents.
Related molecules
- temozolomide — same ATC class L01A — Antineoplastics
- busulfan — same ATC class L01A — Antineoplastics
- treosulfan — same ATC class L01A — Antineoplastics
- chlormethine — same ATC class L01A — Antineoplastics
- melphalan — same ATC class L01A — Antineoplastics
- carmustine — same ATC class L01A — Antineoplastics
Coverage: 23 decisions for bendamustine from 6 agencies, 2010 to 2024. Data to 7 Sep 2026. ATC class L01A — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.